Shulman L, Miller J L, Rose L I
Division of Endocrinology-Metabolism, Hahnemann University School of Medicine, Philadelphia, Pennsylvania.
Am Fam Physician. 1990 May;41(5):1541-6.
Growth hormone from human pituitary glands has been available for 30 years. Because of the scarce supply and the danger of transmitting Creutzfeldt-Jakob disease, use of the hormone was discontinued in 1984. Fortunately, synthetic growth hormone produced with recombinant DNA technology became available in 1985 and eliminated the risk of Creutzfeldt-Jakob disease. Growth hormone is approved for use in the treatment of pituitary deficiency syndromes and, when properly administered at an early stage, is capable of inducing normal skeletal and muscular development. It also has been successfully used to augment growth in patients with Turner's syndrome or constitutional growth delay not associated with obvious growth hormone defects. Side effects are generally not serious, but antibodies to growth hormone develop in about 30 percent of patients.
来自人脑垂体的生长激素已可供使用30年。由于供应稀缺以及传播克雅氏病的风险，该激素的使用于1984年停止。幸运的是，1985年利用重组DNA技术生产的合成生长激素问世，消除了克雅氏病的风险。生长激素被批准用于治疗垂体功能减退综合征，并且在早期适当给药时，能够诱导正常的骨骼和肌肉发育。它也已成功用于促进特纳综合征患者或与明显生长激素缺陷无关的体质性生长迟缓患者的生长。副作用一般不严重，但约30%的患者会产生生长激素抗体。
